Suppr超能文献

高剂量乙胺嗪或单剂量伊维菌素治疗盘尾丝虫病:微丝蚴水平及副作用

Chemotherapy of onchocerciasis with high doses of diethylcarbamazine or a single dose of ivermectin: microfilaria levels and side effects.

作者信息

Albiez E J, Newland H S, White A T, Kaiser A, Greene B M, Taylor H R, Büttner D W

机构信息

Department of Helminthology, Bernhard-Nocht-Institut, Hamburg, FRG.

出版信息

Trop Med Parasitol. 1988 Mar;39(1):19-24.

PMID:3291074
Abstract

Fifty adult male subjects with moderate to heavy onchocerciasis from the Liberian rain forest were selected for a double-blind placebo-controlled chemotherapy study. The effects of high doses of diethylcarbamazine (DEC) - 30 mg/kg/d - over one week preceded by a one week initial treatment with normal oral doses of DEC or DEC lotion were compared with a single dose of ivermectin (150 micrograms/kg) and placebo. During the initial treatment DEC tablets or lotion caused distinctly more frequent and severe reactions than did invermectin. The reactions to ivermectin did not differ from those of the placebo patients. High doses of DEC caused, in about half of the patients, headache, dizziness, nausea or vomiting. DEC markedly increased the number of corneal microfilariae and of corneal opacities compared to ivermectin. All changes resolved with a return to pretreatment findings two months after treatment. The three treatment groups showed no differences at the ten months follow-up. In all treated patients skin microfilaria counts fell almost to zero by the end of the two week therapy. In the ivermectin group microfilaria counts remained significantly lower than in the DEC patients at the two and ten months examinations. In summary, ivermectin was much better tolerated than DEC and had a longer lasting effect on the microfilariae in the skin. Since high doses of DEC were less effective and caused more frequent and severe side effects, this approach cannot be recommended for treatment of onchocerciasis.

摘要

从利比里亚雨林中挑选出50名患有中度至重度盘尾丝虫病的成年男性受试者,进行一项双盲安慰剂对照化疗研究。将高剂量乙胺嗪(DEC)——30毫克/千克/天,持续一周,在此之前先用正常口服剂量的DEC或DEC洗剂进行为期一周的初始治疗——与单剂量伊维菌素(150微克/千克)和安慰剂进行比较。在初始治疗期间,DEC片剂或洗剂引起的反应明显比伊维菌素更频繁、更严重。伊维菌素引起的反应与服用安慰剂的患者没有差异。高剂量的DEC在大约一半的患者中引起头痛、头晕、恶心或呕吐。与伊维菌素相比,DEC显著增加了角膜微丝蚴和角膜混浊的数量。所有变化在治疗后两个月恢复到治疗前的状态。在十个月的随访中,三个治疗组没有差异。在所有接受治疗的患者中,在两周治疗结束时皮肤微丝蚴计数几乎降至零。在两个月和十个月的检查中,伊维菌素组的微丝蚴计数仍显著低于DEC组患者。总之,伊维菌素的耐受性比DEC好得多,并且对皮肤中的微丝蚴有更持久的作用。由于高剂量的DEC效果较差且引起更频繁、更严重的副作用,因此不推荐这种方法用于治疗盘尾丝虫病。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验